The long term health consequences of polycystic ovary syndrome

British Journal of Obstetrics and Gynaecology

Volumn 107, Issue 11, 2000, Pages 1327-1338

  Kelly, Christopher J G ^a   Connell, John M C ^a   Cameron, Iain T ^b   Gould, Gwyn W ^c   Lyall, Helen ^d  

^a WESTERN INFIRMARY   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CYPROTERONE ACETATE; FINASTERIDE; INSULIN DERIVATIVE; METFORMIN; ORAL CONTRACEPTIVE AGENT; SPIRONOLACTONE; THIAZOLIDINE DERIVATIVE;

BLOOD CLOTTING; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; EXERCISE; HYPERANDROGENISM; HYPERTENSION; INSULIN RESISTANCE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; VASCULAR ENDOTHELIUM; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; ENDOTHELINS; FEMALE; HUMANS; HYPERANDROGENISM; HYPERTENSION; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; POLYCYSTIC OVARY SYNDROME;

EID: 0033646368     PISSN: 03065456     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2000.tb11644.x     Document Type: Review

References (154)

1. New perspectives in polycystic ovary syndrome
2. Polycystic ovary syndrome
3. Effects of sex steroids on women's health: Implications for practitioners
4. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome
5. Coronary heart disease risk factors in women with polycystic ovary syndrome
6. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: Results of a case-control study
7. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease
8. Insulin resistance in patients with polycystic ovaries
9. Insulin resistance in nonobese patients with polycystic ovarian disease
10. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome
11. Ethnicity and polycystic ovary syndrome are associated with independent and additive decreases in insulin action in Caribbean-Hispanic women
12. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus
13. Relation of functional ovarian hyperandrogenism to non-insulin dependent diabetes mellitus
14. Metabolic aspects of polycystic ovary syndrome
15. Banting lecture 1988. Role of insulin resistance in human disease
16. Insulin resistance and compensatory hyperinsulinemia: Role in hypertension, dyslipidemia, and coronary heart disease
17. Hyperinsulinemia and cardiovascular risk
18. Relation of components of insulin resistance syndrome to coronary disease risk
19. Low insulin sensitivity is associated with clustering of cardiovascular disease risk factors
20. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion
21. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis
22. Induction of insulin resistance by androgens and estrogens
23. Hyperandrogenisity in women: A prediabetic condition
24. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome
25. Insulin resistance improves in hyperandrogenic women treated with lupron
26. Insulin secretion in polycystic ovarian disease: Effect of ovarian suppression by GnRH agonist
27. The influence of androgens on insulin resistance
28. Insulin resistance-mechanisms, syndromes and implications
29. On the paradox of insulin-induced hyperandrogenism in insulin resistant states
30. Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor
31. Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries
32. Decreases in ovarian cytochrome P450 c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome
33. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system
34. Selective insulin resistance in the polycystic ovary syndrome
35. The role of insulin resistance in polycystic ovary syndrome
36. Ovarian response to hCG stimulation: Insulin resistance/hyperinsulinaemia vs insulin deficiency
37. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome
38. Suppression of serum insulin level by diazoxide does not alter serum testosterone or sex hormone-binding globulin levels in healthy, nonobese women
39. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy
40. Insulin administration alters gonadal steroid metabolism independent of changes in gonadotrophin secretion in insulin-resistant women with the polycystic ovary syndrome
41. Hereditary factors in Stein-Leventhal syndrome
42. Familial polycystic ovarian disease
43. The inheritance of polycystic ovarian disease and possible relationship to premature balding
44. Evidence for a single gene effect in polycystic ovaries and male pattern baldness
45. Polycystic ovaries are inherited as an autosomal dominant trait: Analysis of 29 polycystic ovary syndrome and 10 control families
46. A twin study of polycystic ovary syndrome
47. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene
48. Association of the steroid synthesis gene CYP11 a with polycystic ovary syndrome and hyperandrogenism
49. Linkage and association of insulin gene VNTR regulator polymorphism with polycystic ovary syndrome
50. La virilisme pilaire et son association a l'insuffisance glycolytique (diabete des femmes a barb) [in French]
51. Glucose clamp technique a method of quantifying insulin secretion and resistance
52. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome
53. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome
54. Severe impairment of insulin action in adipocytes from amenorrheic subjects with polycystic ovary syndrome
55. Insulin resistance in polycystic ovary syndrome: Decreased expression of GLUT-4 glucose transporters in adipocytes
56. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome
57. Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity
58. Characterisation of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance and/or hyperinsulinemia
59. Physiological evaluation of factors controlling glucose tolerance in man: Measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose
60. B-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome
61. Defects in B-cell function in functional ovarian hyperandrogenism
62. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in Type 2 diabetes
63. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin dependent diabetes mellitus
64. Prevalence and predictors of risk for Type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women
65. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: A long term follow-up focusing on natural history and circulating hormones
66. Onset of NIDDM occurs at least 4-7 years before clinical diagnosis
67. Undiagnosed NIDDM: Clinical and public health issues
68. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group
69. Intensified multifactorial intervention in patients with Type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study
70. Clinical practice recommendations 2000
71. Hyperinsulinaemia: The key feature of a cardiovascular and metabolic syndrome
72. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease
73. Insulin resistance and fat patterning with ageing: Relationship to metabolic risk factors for cardiovascular disease
74. Regional distribution of body fat, plasma lipoproteins and cardiovascular disease
75. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance
76. Glucose and insulin metabolism in hypertension
77. Clinical implications of insulin resistance syndromes
78. Essential hypertension, metabolic disorders, and insulin resistance
79. The kidney: An unwilling accomplice in syndrome X
80. Vascular insulin abnormalities, hypertension, and accelerated atherosclerosis
81. Clustering of cardiovascular risk factors in confirmed prehypertensive individuals
82. Insulin resistance in hypertension - A relationship with consequences?
83. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome
84. Polycystic ovary syndrome: Lack of hypertension despite profound insulin resistance
85. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: A sign of a pre-hypertensive state?
86. Relationship between insulin resistance and coronary heart disease in diabetes mellitus and the general population: A critical appraisal
87. Metabolism of VLDL, LDL subclasses, Curr Opin Lipidol
88. Insulin resistance and risk factors for coronary heart disease
89. Insulin resistance, hyperinsulinemia, dyslipidemia, hypertension, and accelerated atherosclerosis
90. Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia
91. Insulin resistance: Syndrome or tendency?
92. Relation between lipids and atherosclerosis: Epidemiologic evidence and clinical implications
93. Lipids, diabetes and coronary heart disease: Insights from the Framingham Study
94. High density lipoprotein cholesterol and cardiovascular disease
95. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome
96. Lipid metabolic studies in women with a polycystic ovary syndrome during treatment with a low-dose desogestrel-ethinylestradiol combination
97. Metabolic profile in obese women with the polycystic ovary syndrome
98. Lipid metabolism in women with polycystic ovary syndrome: Possible implications for an increased risk of coronary heart disease
99. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome
100. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: Results of a case-control study
101. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome
102. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries
103. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome
104. Pathogenesis and measurement of insulin resistance in hypertension
105. Insulin mediated skeletal muscle vasodilation is nitric oxide dependent
106. Nitric oxide and cardiovascular disease
107. Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease
108. Impaired endothelium-dependent vasodilatation in women with previous gestational diabetes
109. Obesity/insulin resistance is associated with endothelial dysfunction
110. Troglitazone therapy improves endothelial function in women with polycystic ovary syndrome
111. PAI-1, obesity, insulin resistance and risk of cardiovascular events
112. Insulin resistance syndrome and fibrinolytic activity: The northern Sweden MONICA study
113. Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function
114. PAI-1, obesity, insulin resistance and risk of cardiovascular events
115. Plasma fibrinogen: A new factor of the metabolic syndrome. A population-based study
116. Fibrinogen as a cardiovascular risk factor: A meta analysis and review of the literature
117. The plasminogen activator system in women with polycystic ovary syndrome
118. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome
119. Clinical signs of androgen excess as risk factors for coronary artery disease
120. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization
121. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women
122. Mortality of women with polycystic ovary syndrome at long-term follow-up
123. Consensus statement: Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes
124. MFSR. Prognosis of patients with diabetes mellitus after acute myocardial infarction
125. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome
126. Exercise, glucose transport, and insulin sensitivity
127. Acute exercise induces GLUT 4 translocation in skeletal muscle of normal human subjects and subjects with Type 2 diabetes
128. Polycystic ovary syndrome and bulimia
129. Oral contraceptives, insulin resistance and ischemic vascular disease
130. Update on the metabolic effects of steroidal contraceptives and their relationship to cardiovascular disease risk
131. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome
132. Venous Thromboembolic Disease and Combined Oral Contraceptives: Results of international multicentre case control study
133. Risk of idiopathic cardiovascular death and nonfatal thromboembolism in women using oral contraceptives with differing progestagen components
134. Detection of functional ovarian hyperandrogenism in women with androgen excess
135. The effects of cyproterone acetate and ethinyl oestrodiol on carbohydrate metabolism
136. Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism
137. A prospective randomised trial comparing finasteride to spironolactone in the treatment of hirsute women
138. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome
139. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome
140. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women
141. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome
142. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome
143. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome
144. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome
145. Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome
146. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450 c17 alpha activity and serum androgens
147. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome
148. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein (a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome
149. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome
150. Metformin has direct effects on human ovarian steroidogenesis
151. Effects of biguanide class oral hypoglycemic agents on mouse embryogenesis
152. Pregnancy in established non insulin dependent diabetics. A five and a half year study at Groot Schuur Hospital